secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEXX LABORATORIES INC /DE (IDXX)
CIK:        0000874716
Form:       8-K
Filed at:   2023-08-01T23:59:59+00:00
Accession:  0001157523-23-001198
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEXX Q2 revenue $944M (+10% organic); EPS $2.67 (+71%); raises 2023 guidance
-----------------------------------------------------------------------------

- Q2 revenue $944M, +10% reported and organic; CAG Diagnostics recurring revenue +11% reported, +12% organic.
- EPS $2.67, +71% reported (+77% comparable); includes $0.04 tax benefit and $0.07 negative FX impact.
- Record quarterly premium instrument placements; global installed base grew 11% annually.
- Updated 2023 revenue guidance to $3,660M-$3,715M (8.5%-10% growth), EPS guidance to $9.64-$9.90 (20%-23% reported growth).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874716/000115752323001198/0001157523-23-001198-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874716/000115752323001198/a53494439.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-001198

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer